Not connected to GLP3Planner: GLP3Planner has no connection to “GLP3-B” capsules or any shop selling them through social media ads. We don't sell medication, supplements or peptides and never take orders. For an order or refund, contact the seller or your bank or card provider.

Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #phase 3 Clear filter

Educational Content

View all →
Showing 8 of 8 articles
No articles found matching your search. Try a different term or view all articles.

Retatrutide Clinical Trials: TRIUMPH Program Guide (2026)

TRIUMPH-4 showed 28.7% weight loss at 68 weeks in December 2025. Seven more retatrutide trials report in 2026. Here is the full TRIUMPH program map, how to enroll, and what the timeline means for FDA approval.

Retatrutide Dosage Chart: 2mg to 12mg Week-by-Week Schedule

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Retatrutide Weight Loss: Results, Timeline & What to Expect

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

Retatrutide Results: 24% Weight Loss in 48 Weeks (Trial Data)

Retatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.

Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)

Retatrutide is not FDA-approved. Lilly is reported to plan an FDA filing in early 2027, and a decision in late 2027 or 2028 is our estimate, not Lilly's. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

Retatrutide Phase 3 Weight Loss Results: TRIUMPH Data

A dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.

When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans an FDA filing in early 2027, and FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.

Retatrutide Pen: What We Know About the Injection Device (2026)

Retatrutide is administered by subcutaneous injection in clinical trials, but no FDA-approved commercial pen exists as of October 2026. This explainer covers what the Phase 3 TRIUMPH trials confirm about delivery format, what grey-market pens actually are, and what a future Eli Lilly auto-injector will likely look like.